Among patients with tumor types where germline alterations in HR genes (including BRCA1/BRCA2/PALB2) have been shown to have a functional role (breast, ovarian, pancreas), ORR was 14% (4/29, 95% CI: 3.9–31.7%); three responders had pathogenic germline alterations in BRCA1/2 or PALB2, and the 4th had a pathogenic TP53 mutation and BRCA2 VUS. This evidence concerns the gene PALB2 and neoplasm.